Sean Marett
Corporate Officer/Principal bij BIONTECH SE
Vermogen: 73 M $ op 29-02-2024
Profiel
Sean Marett occupies the position of Chairman of PHMR Ltd.
Mr. Marett is also on the board of Mann Bioinvest Ltd.
and Aicuris Anti-Infective Cures AG and Chief Business & Commercial Officer at BioNTech SE.
In the past Mr. Marett held the position of Chief Operating Officer at BioNTech SE, Principal at Pfizer Inc. and Principal at Wyeth Corp.
(a subsidiary of Pfizer Inc.), Principal at GSK Plc, Chief Business Officer for Evotec SE, Senior Vice President-Business Development for NextPharma Technologies Ltd.
and Principal at UCB Celltech.
Sean Marett received an undergraduate degree from King's College London and an MBA from Manchester Business School.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
BIONTECH SE
0.34% | 31-12-2023 | 815 263 ( 0.34% ) | 73 M $ | 29-02-2024 |
Actieve functies van Sean Marett
Bedrijven | Functie | Begin |
---|---|---|
BIONTECH SE | Corporate Officer/Principal | 01-01-2012 |
Mann Bioinvest Ltd.
Mann Bioinvest Ltd. Financial ConglomeratesFinance Mann Bioinvest Ltd. invests in the life science sector. The company was founded by James Mellon in 2012 and is headquartered in Douglas, the United Kingdom. | Director/Board Member | - |
JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH Medical SpecialtiesHealth Technology JPT Peptide Technologies GmbH provides innovative peptide based products and services for vaccine development, immune monitoring and peptide biomarker discovery. The firm’s products include custom peptides, modified & labeled peptides, clinical peptides, stable isotope-labeled peptides, SPOT peptides, immunogenic peptides, peptide libraries, peptide pools, peptide microarrays, peptide ELISA, enzyme profiling and epitope discovery service. The company was founded in 2004 and is headquartered in Berlin, Germany. | Chief Executive Officer | - |
PHMR Ltd.
PHMR Ltd. Information Technology ServicesTechnology Services Part of UDG Healthcare Ltd. (Dublin), PHMR Ltd. is a healthcare consulting British company that specializes in insight-enabled pricing and market access approaches to ensure successful product launch and life-cycle management. The private company is based in London, UK. The company helps its clients in the healthcare industries build value for their products by using academically-proven analytical methods to find and form clinical, economic, and humanistic evidence. PHMR is an international team of highly qualified health economists and research scientists. The company was founded by Mark Ratcliffe, who has been the CEO since incorporation. PHMR was acquired by UDG Healthcare Ltd. (Dublin) on January 26, 2021 for $43.75 million. | Chairman | 01-01-2017 |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Director/Board Member | 01-02-2021 |
Eerdere bekende functies van Sean Marett
Bedrijven | Functie | Einde |
---|---|---|
KWS BioTest Ltd.
KWS BioTest Ltd. Pharmaceuticals: MajorHealth Technology KWS BioTest Ltd. provides preclinical pharmacology and drug development for human diseases. Its capabilities include clinical biomarkers, cell biology, bioanalytical services, in vivo pharmacology, vaccine development. The company was founded by Williams A. Neil and Trevor Langley in 2004 and is headquartered in Bristol, the United Kingdom. | Director/Board Member | 01-01-2018 |
GSK PLC | Corporate Officer/Principal | - |
PFIZER, INC. | Corporate Officer/Principal | - |
UCB Celltech
UCB Celltech BiotechnologyHealth Technology Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The private company is based in Slough, UK and was founded in 2006. | Corporate Officer/Principal | - |
░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van Sean Marett
King's College London | Undergraduate Degree |
Manchester Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
PFIZER, INC. | Health Technology |
GSK PLC | Health Technology |
EVOTEC SE | Health Technology |
BIONTECH SE | Health Technology |
Bedrijven in privébezit | 9 |
---|---|
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Lorantis Ltd.
Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Lorantis Ltd. used to discover and develop drugs. The company had discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed. It used pursue immunology drug discovery and development programmes to address unmet medical needs. Lorantis was founded in 1998 and was headquartered in Cambridge, UK | Health Technology |
NextPharma Technologies Ltd.
NextPharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology NextPharma Technologies, In. develops, manufactures, packages, and distributes pharmaceutical products and formulations. The firm focuses on lyophilization, sterile fill finish and pellet technologies, and in product manufacturing including cyotoxics, hormones, penicillins, cephalosporins, and controlled drugs. The company was established on October 27, 2000 and is headquartered in London, the United Kingdom. | Health Technology |
KWS BioTest Ltd.
KWS BioTest Ltd. Pharmaceuticals: MajorHealth Technology KWS BioTest Ltd. provides preclinical pharmacology and drug development for human diseases. Its capabilities include clinical biomarkers, cell biology, bioanalytical services, in vivo pharmacology, vaccine development. The company was founded by Williams A. Neil and Trevor Langley in 2004 and is headquartered in Bristol, the United Kingdom. | Health Technology |
JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH Medical SpecialtiesHealth Technology JPT Peptide Technologies GmbH provides innovative peptide based products and services for vaccine development, immune monitoring and peptide biomarker discovery. The firm’s products include custom peptides, modified & labeled peptides, clinical peptides, stable isotope-labeled peptides, SPOT peptides, immunogenic peptides, peptide libraries, peptide pools, peptide microarrays, peptide ELISA, enzyme profiling and epitope discovery service. The company was founded in 2004 and is headquartered in Berlin, Germany. | Health Technology |
UCB Celltech
UCB Celltech BiotechnologyHealth Technology Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The private company is based in Slough, UK and was founded in 2006. | Health Technology |
Mann Bioinvest Ltd.
Mann Bioinvest Ltd. Financial ConglomeratesFinance Mann Bioinvest Ltd. invests in the life science sector. The company was founded by James Mellon in 2012 and is headquartered in Douglas, the United Kingdom. | Finance |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Commercial Services |
PHMR Ltd.
PHMR Ltd. Information Technology ServicesTechnology Services Part of UDG Healthcare Ltd. (Dublin), PHMR Ltd. is a healthcare consulting British company that specializes in insight-enabled pricing and market access approaches to ensure successful product launch and life-cycle management. The private company is based in London, UK. The company helps its clients in the healthcare industries build value for their products by using academically-proven analytical methods to find and form clinical, economic, and humanistic evidence. PHMR is an international team of highly qualified health economists and research scientists. The company was founded by Mark Ratcliffe, who has been the CEO since incorporation. PHMR was acquired by UDG Healthcare Ltd. (Dublin) on January 26, 2021 for $43.75 million. | Technology Services |